| β-Hemoglobinopathies |
BCL11A directly inhibits the expression of γ-globin |
[59–65] |
| Hematological malignancies |
BCL11A functions as an oncogene, high level of BCL11A blocks cell differentiation, inhibits cell apoptosis and promotes cell proliferation |
[53,54,66,67,74–78] |
| Triple negative breast cancer |
BCL11A functions as an oncogene, high level of BCL11A promotes tumor formation |
[10,68,80,81] |
| Non-small cell lung cancer |
BCL11A functions as an oncogene, high level of BCL11A promotes tumor formation, enhances cell migration and invasion |
[13,21,83,84] |
| Glioblastoma |
BCL11A is highly expressed in glioblastoma and the functions of BCL11A are still unknown |
[85] |
| Neuroblastoma |
High level of BCL11A promotes neuroblastoma cell line growth and inhibits apoptosis |
[11] |
| Laryngeal squamous cell carcinoma |
BCL11A has higher single-nucleotide polymorphisms odds ratios and higher plasma concentrations in advanced stage of laryngeal squamous cell carcinoma, but the functions are unknown |
[86] |
| Ovarian cancer |
High level of BCL11A may increase cell apoptosis |
[24] |
| Prostate cancer |
BCL11A knockdown suppresses prostate cancer cell lines proliferation and invasion |
[23] |
| 2p15-p16.1 microdeletion syndrome |
BCL11A haploinsufficiency |
[88–94] |
| Type II diabetes |
BCL11A is highly expressed in Type II diabetes and negatively correlated with insulin secretion |
[95–105] |
